CEO declined to give a backlog number and couldn't size his own China exposure in the same call.
Thesis: Core business ex-Wuxi is genuinely growing: $28.3M in Q4 to $34M guided in Q1 is +20% seq, on OpEx held at $37M with the $8-10M savings delivered. But the whole thesis rides on two things management refuses to size: a radar ramp they call 'off the charts' with a $30-50M target unchanged, and a $135M Wuxi sale pending Shenzhen Stock Exchange and CSRC approval with timing 'uncertain'. Substrate supply, the actual bottleneck, does not loosen until supplier capex lands in 2027.
Verdict: AVOID — Conviction: MEDIUM
Catalyst: Wuxi closing delivers ~$135M cash by late 2026, plus radar shipments scaling from first silicon in December against the unchanged $30-50M 2026 target.
Key Risk: Substrate and packaging capacity stays constrained through 2026 with new supplier capacity only effective 2027; a repeat of the $5M Q4 demand loss while cash burns ~$15M a quarter.
The Tell: Asked what percent of core business remains in China, McClymont answered: 'Probably in the 25% to 30% range, perhaps. Maybe not quite as high as that anymore, actually. I'm not sure.' A CEO who cannot size his own geographic exposure is either avoiding the question or does not know.
Friction Level: MODERATE_FRICTION — Both sides accept the 20% ex-Wuxi core growth and the $5M-to-sub-$1M substrate relief. Disagreement is whether a CEO who won't quantify backlog, radar ramp timing, or core China exposure can be underwritten at all.
2025Q4 · Feb 20, 2026
4 of 5 readings agreed4 AVOID · 1 HOLDRead the full call
Core Up 20%, Everything Else Left Unquantified
Core business ex-Wuxi is genuinely growing: $28.3M in Q4 to $34M guided in Q1 is +20% seq, on OpEx held at $37M with the $8-10M savings delivered. But the whole thesis rides on two things management refuses to size: a radar ramp they call 'off the charts' with a $30-50M target unchanged, and a $135M Wuxi sale pending Shenzhen Stock Exchange and CSRC approval with timing 'uncertain'. Substrate supply, the actual bottleneck, does not loosen until supplier capex lands in 2027.
Asked what percent of core business remains in China, McClymont answered: 'Probably in the 25% to 30% range, perhaps. Maybe not quite as high as that anymore, actually. I'm not sure.' A CEO who cannot size his own geographic exposure is either avoiding the question or does not know.
Asked directly for a backlog update, the CEO said they 'only really update our strategic backlog once a year' and gave 'no quantifiable update right now.' The 50M unit figure carries 'once we are beyond the ramp-up phase' and the $100M radar mark has no date. Sell a pipeline without numbers and it becomes whatever the listener needs.
Substrate and packaging shortages cost ~$5M in Q4, ~$1M still at risk in Q1, and management says supplier capacity investments 'begin to take effect in 2027' with only 'best visibility we have.' AI chip demand is the cause and does not go away 'anytime soon.'
Wuxi falls from $29.7M to $21M on EV subsidy cuts and Chinese New Year. Core China exposure is stated as '25% to 30% range, perhaps' then walked back to 'I'm not sure.' The ex-Wuxi growth print obscures unresolved China concentration.
Second substrate vendor and second packaging house qualified, giving four routing combinations; second-source foundries being ported for China-for-China and non-China supply. Risk fell from $5M to under $1M in one quarter.
CEO says momentum and 'phenomenal' traction while FY2025 revenue is $217.4M and Q4 is flat year-over-year, with a $12.4M quarterly net loss and radar still 'relatively small volume.'
-75
EVASIVE"Superlatives ('phenomenal' three times, 'off the charts') attached to questions he refuses to number: 'no quantifiable update right now' on backlog, 'probably... perhaps... I'm not sure' on core China exposure, 'a little early to call exactly when' on the $100M radar mark."
CFO gave hard numbers ($29.7M Wuxi, $36.8M OpEx, $15.5M cash decline, $55M midpoint) while the CEO deflected every request to size backlog, radar ramp slope, and China exposure.
Wuxi closing delivers ~$135M cash by late 2026, plus radar shipments scaling from first silicon in December against the unchanged $30-50M 2026 target.
Substrate and packaging capacity stays constrained through 2026 with new supplier capacity only effective 2027; a repeat of the $5M Q4 demand loss while cash burns ~$15M a quarter.
“indie's fourth quarter revenue was $58 million, exceeding the midpoint of our outlook by $1 million, representing sequential growth of approximately 8% and flat compared to the prior year period, bringing our full year revenue to $217.4 million.”
“We expect to deliver total revenues between $52 million to $58 million with $55 million at the midpoint.”
Figures are extracted from the transcripts and checked in code: every quote appears word for word. Descriptive only: none of this feeds the verdict.
Q4 revenue of $58M beat midpoint by $1M at 8% seq growth, OpEx landed at the guided $36.8M after hitting the full $8-10M savings target, and non-GAAP operating loss narrowed to $10.1M from $14.2M a year ago. Core business is guided up 20% seq to $34M in Q1. Radar Gen 8 shipped first silicon in December to a Tier 1 with OEM wins across Europe, North America, Japan, China and India, demand 'well above 50 million units annual' at steady state, $30-50M in 2026 with a ramp through 2029. Substrate loss cut from $5M to under $1M via four substrate/packaging combinations. OpEx flat through 2026 with tooling bumps under $1M. Wuxi sale brings $135M cash.
FY2025 revenue $217.4M with Q4 flat year-over-year. Radar is 'still relatively small volume' and the $30-50M target is unchanged: 'nothing really has changed in the short term.' Backlog gets 'no quantifiable update.' Core China exposure is '25% to 30%... I'm not sure.' Wuxi sale needs Shenzhen Stock Exchange and CSRC approval with timing 'uncertain' while cash fell $15.5M to $155.7M in one quarter, $6.8M of that convertible interest. Substrate capacity relief lands 2027. Quantum shipped $1M, robotics zero. Adjectives: 'phenomenal' x3, 'off the charts,' 'absolutely phenomenal.'
Backlog Quality
Analyst asked point-blank for backlog numbers. Answer: 'no quantifiable update right now.' The $100M radar milestone gets 'probably a little early to call exactly when.' Unquantifiable demand cannot be sized.
Say/Do Gap
'Off the charts' traction language against flat year-over-year Q4 revenue, $12.4M quarterly net loss, and radar still small volume in Q4 and Q1.
Capacity Ceiling
AI-driven substrate tightness persists 'anytime soon'; supplier capacity investments only take effect in 2027 while indie must 'manage through this '26 year.'
China Revenue Decline Masked
Wuxi $29.7M to $21M, and core China exposure unquantified by the CEO himself on direct question. Divestiture approval remains uncertain.
AI Label Without Substance
Quantum $1M in 2025 to ~$3M in 2026, robotics named (Figure AI, Unitree) with no dollar figure. Actual AI link is negative: AI chip demand crowds out substrate capacity.
AVOID. The numbers I can verify are mixed but not broken: core +20% seq, OpEx at guide, op loss narrowing $4M y/y. The numbers I cannot verify are the entire thesis: radar ramp magnitude, backlog, core China exposure, and whether CSRC approves a $135M sale that funds the ramp. Two binaries stacked on a business burning ~$15M of cash a quarter with a $155.7M balance. I cannot size risk I cannot measure. Wait for a quantified backlog update or a closed Wuxi sale before putting capital to work.